Trinity Biotech plc Stock

Equities

TRIB

US8964385046

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:30:00 2024-05-31 pm EDT 5-day change 1st Jan Change
1.65 USD -0.60% Intraday chart for Trinity Biotech plc -2.37% -23.08%
Sales 2024 * 62.7M Sales 2025 * 71M Capitalization 15.62M
Net income 2024 * -19M Net income 2025 * -9M EV / Sales 2024 * 0.25 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.22 x
P/E ratio 2024 *
-0.76 x
P/E ratio 2025 *
-1.59 x
Employees 380
Yield 2024 *
-
Yield 2025 *
-
Free-Float 89.35%
More Fundamentals * Assessed data
Dynamic Chart
European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Wednesday Trading MT
Transcript : Trinity Biotech plc, Q1 2024 Earnings Call, May 23, 2024
Trinity Biotech plc Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading MT
Trinity Biotech plc Receives Substantial Additional Orders for TrinScreen HIV CI
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading MT
Trinity Biotech Announces Strategic Collaboration with PulseAI CI
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading MT
Trinity Biotech Secures Additional Orders For TrinScreen HIV Rapid Test Product MT
Trinity Biotech plc Revises Revenue Guidance for the Fourth Quarter of 2024 CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3% MT
More news
1 day-0.60%
1 week-2.37%
1 month-5.71%
3 months-23.26%
6 months-35.29%
Current year-23.08%
More quotes
1 week
1.60
Extreme 1.6
1.81
1 month
1.49
Extreme 1.49
2.08
Current year
1.49
Extreme 1.49
3.35
1 year
1.49
Extreme 1.49
5.50
3 years
1.49
Extreme 1.49
17.40
5 years
1.49
Extreme 1.49
34.11
10 years
1.49
Extreme 1.49
120.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 43 20-11-16
Founder 68 92-05-31
Chief Tech/Sci/R&D Officer 40 15-08-31
Members of the board TitleAgeSince
Founder 68 92-05-31
Director/Board Member 65 95-09-30
Director/Board Member 66 22-10-25
More insiders
Date Price Change Volume
24-05-31 1.65 -0.60% 42,519
24-05-30 1.66 +2.47% 33,989
24-05-29 1.62 -0.61% 1,089
24-05-28 1.63 -3.55% 9,921
24-05-24 1.69 +3.68% 5,881

Delayed Quote Nasdaq, May 31, 2024 at 04:30 pm EDT

More quotes
Trinity Biotech PLC is an Ireland-based develops, acquires, manufactures and markets medical diagnostic systems, including both reagents and instrumentation for the clinical laboratory and point-of-care segments of the diagnostic market. The Company's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. Its segments include the Americas and Rest of World. It is a provider of raw materials to the life sciences and research industries globally. It also operates a licensed reference laboratory that specializes in diagnostics for autoimmune diseases. Its POC brands include Uni-Gold, Recombigen, MarDx, FlexTrans, Premier and Ultra. Its clinical laboratory brands include ImmuBlot, ImmuGlo, ImmuLisa, OTOblot and EZ. The Company manufactures kits for the detection of specialty and esoteric biomarkers of infectious diseases and other associated laboratory products.
More about the company